CX3CL1 and inflammatory bowel disease: CX3CL1 was recently observed in the colon of IBD patients and Oxa-treated mice, whereas the use of anti-CX3CL1 mAb can significantly improve colitis symptoms by dislodging the crawling monocytes and repressing leukocyte activation and infiltration [29].